Compass Pathways Gets New Patent for Psilocybin Treatment. The Stock Extends Gains.

Compass Pathways Gets New Patent for Psilocybin Treatment. The Stock Extends Gains.
·1 min read

Shares of Compass Pathways extended gains early Wednesday after the biotech company received a new patent for its crystalline psilocybin. U.S. listed stock of Compass Pathways (ticker: CMPS) rose 0.6% in premarket trading Wednesday after jumping 7% on Tuesday. This is the first patent for claims covering its Form A hydrate psilocybin, Compass Pathways said in a press release.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting